Herein, we report a multicenter real-life experience on patients with sJIA and AOSD in the long term, evaluating ANA effectiveness in terms of drug retention rate (DRR) along with predictive factors associated with treatment withdrawal. This evidence concerns the gene BTG3 and adult-onset Still disease.